The Answer
Twenty one out of the top Thirty five Pharmaceutical companies are American.
This is the legal segment
regarding illicit or previously illicit dugs some other time.
From WIKIPEDIA
| Rank[N 1] | Company | Largest Market Cap (USD billions) | Market Cap in 2018 (USD billions) | Market Cap in 2017 (USD billions) | Market Cap in 2016 (USD billions)[1][2] | Market Cap in 2015 (USD billions)[3] | Market Cap in 2014 (USD billions)[4] | Market Cap in 2013 (USD billions) |
|---|---|---|---|---|---|---|---|---|
1  |
 Johnson & Johnson[P]NYSE: JNJ |
397.4 (Jan 2018) | 346.1 | 375.4 | 314.1 | 284.2 | 277.8 | 258.3 |
| 2 |
Pfizer[P] NYSE: PFE |
310.5 (Jul 2000) | 259.7 | 215.9 | 196.3 | 199.3 | 205.4 | 196.0 |
| 3 |
 Roche[P]SIX: ROG |
263.6 (Feb 2014) | 209.3 | 216.7 | 192.1 | 234.7 | 258.5 | 240.3 |
4  2 |
Merck & Co.[P] NYSE: MRK |
213.6 (Nov 2018) | 205.8 | 153.3 | 164.3 | 147.6 | 166.9 | 146.5 |
5  1 |
Novartis[P] NYSE: NVS |
275.2 (Jul 2015) | 200.0 | 196.7 | 170.5 | 206.1 | 229.8 | 195.0 |
| 6 1 |
AbbVie[P] NYSE: ABBV |
196.2 (Jan 2018) | 146.3 | 154.4 | 100.2 | 96.8 | 104.1 | 83.8 |
| 7 |
Amgen[B] NASDAQ: AMGN |
143.0 (Jan 2018) | 128.8 | 126.2 | 108.9 | 122.5 | 93.1 | 78.7 |
| 8 |
Abbott Laboratories[P] NYSE: ABT |
130.2 (Dec 2018) | 126.8 | 99.3 | 56.4 | 67.0 | 67.9 | 59.3 |
| 9 1 |
Eli Lilly & Co[P] NYSE: LLY |
131.2 (Feb 2019) | 125.6 | 93.0 | 80.9 | 93.4 | 76.6 | 57.0 |
| 10 1 |
 Novo Nordisk[P]NYSE: NVO |
159.6 (Aug 2015) | 111.9 | 131.2 | 92.6 | 153.9 | 125.4 | 19.6 |
| 11 |
 Sanofi[P]NYSE: SNY |
151.3 (Sep 2014) | 108.4 | 108.2 | 101.8 | 111.8 | 138.1 | 142.0 |
| 12 2 |
 AstraZeneca[P]NYSE: AZN |
105.1 (Nov 2018) | 96.2 | 87.9 | 68.8 | 85.8 | 88.9 | 74.6 |
| 13 2 |
GlaxoSmithKline[P] NYSE: GSK |
174.9 (May 2006) | 94.8 | 87.9 | 93.3 | 97.6 | 128.9 | 129.6 |
| 14 1 |
Bristol-Myers Squibb[P] NASDAQ: BMY |
128.3 (Jul 2016) | 85.0 | 100.3 | 98.2 | 114.8 | 97.6 | 87.2 |
| 15 2 |
Gilead Sciences[B] NASDAQ: GILD |
179.6 (Jun 2013) | 81.6 | 93.6 | 96.6 | 145.8 | 109.0 | 78.4 |
| 16 |
Biogen[B] NASDAQ: BIIB |
111.7 (Mar 2015) | 63.5 | 67.4 | 61.6 | 68.3 | 79.7 | 66.1 |
| 17 3 |
 Bayer[B]FWB: BAYN |
129.0 (Mar 2015) | 63.1 | 101.9 | 85.3 | 103.2 | 113.2 | 117.4 |
| 18 1 |
Stryker Corporation[P] NYSE: SYK |
67.6 (Feb 2019) | 58.6 | 58.0 | 45.1 | 34.7 | 35.7 | 28.4 |
| 19 2 |
 Shire Pharmaceuticals[P]NASDAQ: SHPG |
62.0 (Sep 2014) | 53.0 | 47.0 | 50.1 | 41.0 | 42.4 | 28.1 |
| 20 |
 Takeda Pharmaceutical [P]NASDAQ: TYO |
59.6 (June 2007) | 52.9 | 40.2 | 45.6 | 47.8 | 37.5 | 34.3 |
| 21 2 |
Celgene[B] NASDAQ: CELG |
115.3 (Oct 2017) | 46.6 | 82.2 | 91.4 | 94.1 | 89.5 | 69.2 |
| 22 4 |
Allergan[P] NYSE: AGN |
133.5 (Jul 2015) | 46.2 | 54.4 | 72.7 | 123.3 | 68.5 | 29.3 |
| 23 1 |
Illumina [B] NASDAQ: ILMN |
54.0 (Sept 2018) | 44.1 | 40.2 | 39.4 | 35.4 | 28.6 | 25.7 |
| 24 1 |
Vertex Pharmaceuticals[P] NASDAQ: VRTX |
49.1 (Sept 2018) | 42.2 | 37.9 | 18.3 | 31.0 | 28.7 | 17.4 |
| 25 1 |
Zoetis[P] NASDAQ: ZTS |
46.1 (Nov 2018) | 41.4 | 35.1 | 26.4 | 23.8 | 21.6 | 16.3 |
| 26 1 |
Regeneron Pharmaceuticals[P] NASDAQ: REGN |
61.4 (Aug 2015) | 40.3 | 40.4 | 39.3 | 56.5 | 42.0 | 27.4 |
| 27 1 |
Astellas[P] TYO: 4503 |
35.9 (Nov 2017) | 23.8 | 29.3 | 25.7 | 40.6 | 35.8 | 27.6 |
| 28 2 |
Eisai Pharmaceutical [P] TYO: 4523 |
24.7 (June 2018) | 23.0 | 24.5 | 37.3 | 28.8 | 30.2 | 28.7 |
| 29 |
Daiichi Sankyo [P] NASDAQ: DSNKY |
27.9 (June 2018) | 22.7 | 27.5 | 35.3 | 38.8 | 33.2 | 28.7 |
| 30 1 |
Alexion Pharmaceuticals[P] NASDAQ: ALXN |
47.0 (Jul 2015) | 21.7 | 26.7 | 27.4 | 43.1 | 36.7 | 26.0 |
| 31 1 |
BioMarin [P] NASDAQ: BMRN |
24.0 (Jul 2015) | 15.1 | 18.3 | 20.4 | 13.8 | 12.9 | 10.8 |
| 32 1 |
Mylan [P] NASDAQ: MYL |
37.2 (Apr 2015) | 14.1 | 27.5 | 30.3 | 38.8 | 33.2 | 35.7 |
| 33 |
Incyte [P] NASDAQ: INCY |
31.2 (Mar 2017) | 13.5 | 18.3 | 15.4 | 10.6 | 7.3 | 4.6 |
| 34 |
Perrigo [P] NASDAQ: PRGO |
29.0 (May 2017) | 5.5 | 9.9 | 9.5 | 8.3 | 14.7 | 12.2 |
| 35 |
United Therapeutics [P] Template:UTHR |
6.0 (May 2018) | 5.5 | 8.9 | 7.5 | 8.3 | 11.7 | 7.2 |
No comments:
Post a Comment